Omalizumab and treatment-resistant chronic spontaneous urticaria

Akyol A., ÖKTEM A., AKAY B. N., KUNDAKCI N., BOYVAT A.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, vol.49, no.3, pp.180-183, 2015 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.4274/turkderm.22587
  • Journal Name: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.180-183
  • Keywords: Chronic spontaneous urticaria, chronic urticaria, omalizumab, anti-IgE, treatment, DOSE OMALIZUMAB, CASE SERIES, EFFICACY, THERAPY, IGE
  • Ankara University Affiliated: Yes

Abstract

Background and Design: Humanized monoclonal antibody omalizumab was developed for the treatment of moderate-to-severe asthma. However, recently, reports on the successful use of omalizumab in the treatment of resistant chronic urticaria are increasing in the literature.